SomaLogic, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLGC research report →
Companywww.somalogic.com
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
- CEO
- Stephen A. Williams BS, MB,
- IPO
- 2021
- Employees
- 451
- HQ
- Boulder, CO, US
Price Chart
Valuation
- Market Cap
- $396.23M
- P/E
- -3.54
- P/S
- 4.06
- P/B
- 0.69
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 55.60%
- Op Margin
- -179.96%
- Net Margin
- -111.77%
- ROE
- -18.59%
- ROIC
- -28.79%
Growth & Income
- Revenue
- $97.67M · 19.65%
- Net Income
- $-109,157,000 · -26.48%
- EPS
- $-0.59 · 6.35%
- Op Income
- $-175,761,000
- FCF YoY
- -142.29%
Performance & Tape
- 52W High
- $3.79
- 52W Low
- $1.73
- 50D MA
- $2.43
- 200D MA
- $2.45
- Beta
- 1.64
- Avg Volume
- 2.27M
Get TickerSpark's AI analysis on SLGC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 24 | Taich Adam | sell | 110,000 |
| Jan 5, 24 | Taich Adam | sell | 185,812 |
| Jan 5, 24 | Taich Adam | sell | 95,000 |
| Jan 5, 24 | Taich Adam | sell | 48,425 |
| Jan 5, 24 | Taich Adam | sell | 855,000 |
| Jan 5, 24 | Taich Adam | sell | 145,000 |
| Jan 5, 24 | Taich Adam | sell | 592,000 |
| Jan 5, 24 | Taich Adam | sell | 150,000 |
| Jan 5, 24 | Ryan Jason | sell | 14,650 |
| Jan 5, 24 | Ryan Jason | sell | 3,400 |
Our SLGC Coverage
We haven't published any research on SLGC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLGC Report →